ReviewInsects2023
Biotechnological Potential of Microorganisms for Mosquito Population Control and Reduction in Vector Competence.
Review in Insects, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of insect-specific viruses on transmission, infection, and replication of arboviruses in co-infected mosquitoes: a systematic review.Parasites & vectors · 2026Pooled it
- Applied Nanobiotechnology for Vector-borne Disease Management: Drug Delivery, Diagnostics, and Sustainable Vector Control.Applied biochemistry and biotechnology · 2026Review
- Decoding the genome of Bacillus thuringiensis subsp. israelensis VCRC B668 to understand its mosquitocidal potential for biopesticide development.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Genomic, biological, and chemical studies of Streptomyces sp. LaBMicrA B280 isolated from the rhizosphere of Inga edulis Martius in the Amazon.Antonie van Leeuwenhoek · 2026Article
- Exploring the efficacy of new potential bio-insecticides produced by Penicillium oxalicum against Culex pipiens larvae.BMC microbiology · 2026Article
- Field trial finds promising evidence on Spinosad: a bio-larvicide for mosquito control in urban settings in Bengaluru, India.Malaria journal · 2025Article
- Article
- Genomic and morphological features of an Amazonian Bacillus thuringiensis with mosquito larvicidal activity.AMB Express · 2025Article
- Article
- Review
- Isolation of a NovelJournal of fungi (Basel, Switzerland) · 2024Article
- The potential biological activities ofFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mosquitoes transmit pathogens that cause human diseases such as malaria, dengue fever, chikungunya, yellow fever, Zika fever, and filariasis. Biotechnological approaches using microorganisms have a significant potential to control mosquito populations and reduce their vector competence, making them alternatives to synthetic insecticides. Ongoing research has identified many microorganisms that can be used effectively to control mosquito populations and disease transmission. However, the successful implementation of these newly proposed approaches requires a thorough understanding of the multipronged microorganism-mosquito-pathogen-environment interactions. Although much has been achieved in discovering new entomopathogenic microorganisms, antipathogen compounds, and their mechanisms of action, only a few have been turned into viable products for mosquito control. There is a discrepancy between the number of microorganisms with the potential for the development of new insecticides and/or antipathogen products and the actual available products, highlighting the need for investments in the intersection of basic research and biotechnology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.